Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oculis Holding AG's ROE % for the quarter that ended in Mar. 2026 was -59.50%. Oculis Holding AG's PB Ratio for the quarter that ended in Mar. 2026 was 5.67.
Oculis Holding AG's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -10.49%.
Oculis Holding AG ROE % Adjusted to Book Value Related Terms
Oculis Holding AG ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Oculis Holding AG's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oculis Holding AG ROE % Adjusted to Book Value Chart
FRA:CR5 vs NVCT, AURA, CADL: ROE % Adjusted to Book Value Comparison
For the Biotechnology subindustry, Oculis Holding AG's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oculis Holding AG ROE % Adjusted to Book Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oculis Holding AG's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Oculis Holding AG's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -10.49% mean?
Oculis Holding AG (FRA:CR5) has a ROE % Adjusted to Book Value of -10.49% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Oculis Holding AG and its competitors.
Is Oculis Holding AG's ROE % Adjusted to Book Value too high?
Oculis Holding AG's current ROE % Adjusted to Book Value is -10.49%. Overall, Oculis Holding AG has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Oculis Holding AG's ROE % Adjusted to Book Value compare to NVCT and AURA?
Oculis Holding AG's ROE % Adjusted to Book Value of -10.49% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Oculis Holding AG and its competitors. Oculis Holding AG's current ROE % Adjusted to Book Value is -10.49%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oculis Holding AG stock overvalued right now?
Oculis Holding AG (FRA:CR5) has a current ROE % Adjusted to Book Value of -10.49%. The current ROE % Adjusted to Book Value is -10.49%. Oculis Holding AG's overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Oculis Holding AG (FRA:CR5), the current ROE % Adjusted to Book Value is -10.49% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
22GF Score
Get the complete analysis for FRA:CR5
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:CR5 has been successfully added to your 
